Browse the evidence

Participants receiving cagrilintide-semaglutide were more likely to achieve weight-loss targets of 5%, 20%, 25%, and 30% or more compared to placebo.

Cagrilintide-semaglutide may help patients achieve significant weight-loss goals.

In adults with obesity, treatment with 36 mg of orforglipron for 72 weeks led to a mean body weight reduction of -11.2%, significantly greater than the -2.1% reduction with placebo (P<0.001).

Orforglipron may be an effective treatment option for weight loss in obese adults.

54.6% of patients in the orforglipron 36-mg group achieved a weight reduction of 10% or more, compared to 12.9% in the placebo group.

A significant proportion of obese adults may achieve clinically meaningful weight loss with orforglipron.

Orforglipron treatment resulted in significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared to placebo.

Orforglipron may improve several cardiovascular and metabolic risk factors in obese adults.

All intermittent fasting and continuous energy restriction diet strategies reduced body weight when compared with ad-libitum diet.

Intermittent fasting and continuous energy restriction can be effective strategies for weight loss in diverse populations.

Alternate day fasting was the only form of intermittent fasting diet strategy to show benefit in body weight reduction compared with continuous energy restriction.

Alternate day fasting may be a more effective intermittent fasting strategy for weight loss compared to continuous energy restriction.

In comparisons between intermittent fasting strategies, alternate day fasting lowered total cholesterol, triglycerides, and non-high density lipoprotein compared with time restricted eating.

Alternate day fasting may improve lipid profiles more effectively than time restricted eating.

Oral semaglutide at a dose of 25 mg once daily resulted in a mean reduction in body weight of -13.6% from baseline to week 64.

Oral semaglutide may be an effective treatment option for weight loss in adults with obesity.

Participants in the oral semaglutide group were significantly more likely to achieve body-weight reductions of 5% or more, 10% or more, 15% or more, and 20% or more compared to the placebo group.

Oral semaglutide may help patients achieve significant weight loss milestones.

In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg for 32 weeks led to a mean percentage change in body weight from baseline of -10.09%.

Mazdutide may be an effective treatment option for weight loss in adults with obesity or overweight.

In the 6-mg mazdutide group, the mean percentage change in body weight from baseline at week 32 was -12.55%.

Higher doses of mazdutide may lead to greater weight loss in adults with obesity or overweight.

73.9% of participants in the 4-mg mazdutide group achieved a weight reduction of at least 5% at week 32.

A significant proportion of adults with obesity or overweight may benefit from mazdutide treatment.

Nutrient-Stimulated Hormone (NuSH) therapies, specifically GLP-1 and dual/triple agonists, significantly improve clinical outcomes and functional capacity in heart failure with preserved ejection fraction (HFpEF) by reducing cardiometabolic burden and systemic inflammation, independent of weight loss alone.

If you have heart failure with preserved ejection fraction (HFpEF) and obesity, current guidelines increasingly support using GLP-1 based therapies (like semaglutide) as a core treatment, not just for weight loss but to protect your heart and kidneys. These drugs work by resetting your metabolism and reducing inflammation, offering benefits that go beyond just shedding pounds. While lifestyle changes are still important, they are often not enough on their own to overcome the body's resistance to weight loss in this specific condition. Consult your cardiologist about whether NuSH therapy is appropriate for your specific phenotype, especially if you have co-existing conditions like sleep apnea or kidney disease.

94.2% of patients achieved ≥ 5% weight loss after 6 months of tirzepatide treatment.

Practitioners can expect a high rate of significant weight loss among patients using tirzepatide.

The 5:2 total diet replacement (5:2TDR) resulted in a weight loss of -0.9 kg after 26 weeks, while the once-daily meal-replacement (DMR) group experienced a weight regain of 3.5 kg, leading to a between-group difference of -4.4 kg.

Practitioners may consider recommending 5:2TDR for better weight maintenance outcomes compared to DMR.

Both dietary interventions (5:2TDR and DMR) maintained weight losses greater than 15 kg below baseline at 26, 52, and 78 weeks.

Both interventions can be effective for long-term weight maintenance.

Structured dietary weight-loss maintenance (WLM) is well accepted by participants.

Practitioners can confidently implement these dietary strategies knowing they are well received.

Semaglutide, tirzepatide, and retatrutide achieve placebo-subtracted bodyweight loss of up to 10.8%, 17.8%, and 22.1%, respectively, in adults after 48-72 weeks.

These medications can significantly aid in weight loss for adults with obesity.

Semaglutide reduces body mass index mean by up to 16.7% in adolescents with obesity after 68 weeks.

Semaglutide can be effective for weight management in adolescents with obesity.

Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference -16.03, 95% CI -18.91 to -13.14) compared to placebo.

Practitioners can consider tirzepatide as an effective option for weight loss in adults with obesity.

Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.

Tirzepatide may be particularly effective for helping patients achieve significant weight loss goals.

At 5-6 months, the mean weight reduction was 7.9%, with 56% of participants achieving more than 5% weight loss.

Phentermine/topiramate ER can be effective for weight loss in obese patients.

At 12 months, patients who persisted in treatment experienced an average weight loss of 9.6%, with 65% surpassing a 5% weight loss.

Long-term adherence to treatment can lead to significant weight loss.

Muscle mass can be significantly preserved by integrating resistance training, adequate protein intake, and body composition monitoring into weight-loss treatment programs.

Incorporating resistance training and proper nutrition can help maintain muscle mass during weight loss efforts.